{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:21:22Z","timestamp":1785280882088,"version":"3.55.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008568","name":"Norske Kvinners Sanitetsforening","doi-asserted-by":"publisher","award":["H2\/2018"],"award-info":[{"award-number":["H2\/2018"]}],"id":[{"id":"10.13039\/501100008568","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lillehammer Hospital for Rheumatic Diseases"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Patients with autoimmune arthritis (AA) are at increased risk for impaired cardiac function and heart failure. This may be partly due to the effect of inflammation in heart function. The impact of antirheumatic drugs on cardiac dysfunction in AA remains controversial. Therefore, we aimed to examine effects of antirheumatic treatment on serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in AA patients and its relationship to inflammatory markers.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>We examined 115 patients with AA (64 rheumatoid arthritis (RA), 31 psoriatic arthritis and 20 ankylosis spondylitis) starting with methotrexate (MTX) monotherapy or tumor necrosis factor inhibitors (TNFi) with or without MTX co-medication. NT-proBNP (measured in serum by ECLIA from Roche Diagnostics), and other clinical and laboratory parameters were evaluated at baseline, after 6 weeks and 6 months of treatment.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>NT-proBNP levels did not change significantly after 6 weeks and 6 months of antirheumatic therapy (p<jats:sub>baseline-6weeks<\/jats:sub>= 0.939; p<jats:sub>baseline-6months<\/jats:sub>= 0.485), although there was a modest improvement from 6 weeks to 6 months in the MTX only treatment group (median difference = -18.2 [95% CI = -32.3 to -4.06], p = 0.013). There was no difference in the effects of MTX monotherapy and TNFi regimen on NT-proBNP levels. The changes in NT-proBNP after antirheumatic treatment positively correlated with changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Baseline NT-proBNP levels were related to baseline CRP and ESR levels, and some other established markers of disease activities in crude analyses.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>Circulating levels of NT-proBNP were related to established inflammatory markers at baseline, and the changes in NT-proBNP after antirheumatic treatment were positively related to these markers. Nevertheless, antirheumatic therapy did not seem to affect NT-proBNP levels compared to baseline, even though inflammatory markers significantly improved.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0253793","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T17:28:04Z","timestamp":1624642084000},"page":"e0253793","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-4031","authenticated-orcid":true,"given":"Thao H. P.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Wang","family":"Fagerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia","family":"Deyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnbj\u00f8rg","family":"Hjeltnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Hollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro \u00d8","family":"Eilertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"issue":"3","key":"pone.0253793.ref001","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrcardio.2014.206","article-title":"Cardiorheumatology: cardiac involvement in systemic rheumatic disease","volume":"12","author":"M Prasad","year":"2015","journal-title":"Nature reviews cardiology"},{"issue":"2","key":"pone.0253793.ref002","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ehjcvp\/pvz033","article-title":"Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"6","author":"I Hollan","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"pone.0253793.ref003","doi-asserted-by":"crossref","first-page":"e007227","DOI":"10.1161\/JAHA.117.007227","article-title":"Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study","volume":"7","author":"U Khalid","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"pone.0253793.ref004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta\u2010Analysis of Observational Studies","volume":"69","author":"A Polachek","year":"2017","journal-title":"Arthritis care & research"},{"issue":"1","key":"pone.0253793.ref005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semarthrit.2014.02.004","article-title":"Diastolic left ventricular dysfunction in ankylosing spondylitis\u2014a systematic review and meta-analysis","volume":"44","author":"SC Heslinga","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"pone.0253793.ref006","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/2047487319870344","article-title":"Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies","volume":"27","author":"A Aimo","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"pone.0253793.ref007","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","article-title":"Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure","volume":"69","author":"\u00c4 Mantel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"pone.0253793.ref008","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1002\/art.21349","article-title":"How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?","volume":"52","author":"C Crowson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"pone.0253793.ref009","article-title":"Incidence of and Risk Factors for Heart Failure in Patients with Psoriatic Disease\u2013A Cohort Study","author":"S Koppikar","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"4","key":"pone.0253793.ref010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A Novel Paradigm for Heart Failure With Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation","volume":"62","author":"WJ Paulus","year":"2013","journal-title":"J. Am. Coll"},{"issue":"16","key":"pone.0253793.ref011","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","article-title":"Endothelial dysfunction, arterial stiffness, and heart failure","volume":"60","author":"CN Marti","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0253793.ref012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejheart.2003.12.015","article-title":"Essential biochemistry and physiology of (NT\u2010pro)BNP","volume":"6","author":"C Hall","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"pone.0253793.ref013","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"P Ponikowski","year":"2016","journal-title":"European Heart Journal"},{"key":"pone.0253793.ref014","first-page":"e1054","article-title":"Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure","volume":"135","author":"SL Chow","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"pone.0253793.ref015","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/annrheumdis-2012-202848","article-title":"N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR)","volume":"73","author":"H Mirjafari","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0253793.ref016","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3899\/jrheum.130713","article-title":"Inflammation and Disease Activity are Associated with High Circulating Cardiac Markers in Rheumatoid Arthritis Independently of Traditional Cardiovascular Risk Factors","volume":"41","author":"J Avouac","year":"2014","journal-title":"J Rheumatol"},{"key":"pone.0253793.ref017","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10067-013-2182-x","article-title":"NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study","volume":"32","author":"JCB Moraes","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"3","key":"pone.0253793.ref018","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10554-020-02057-3","article-title":"Subclinical ventricular dysfunction in rheumatoid arthritis","volume":"37","author":"P Rodrigues","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"pone.0253793.ref019","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.yjmcc.2004.01.001","article-title":"Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase","volume":"36","author":"K Ma","year":"2004","journal-title":"J. Mol. Cell. Cardiol"},{"key":"pone.0253793.ref020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure","volume":"34","author":"A Hanna","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9","key":"pone.0253793.ref021","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.41293","article-title":"Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High\u2010Risk Lesions","volume":"72","author":"GA Karpouzas","year":"2020","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"pone.0253793.ref022","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/annrheumdis-2020-217653","article-title":"Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-na\u00efve, early rheumatoid arthritis","volume":"79","author":"S Plein","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0253793.ref023","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/ard.2007.086777","article-title":"Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor a blockade","volume":"68","author":"IC van Eijk","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"pone.0253793.ref024","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/jcm9103145","article-title":"The Effect of Anti-TNF Therapy on Cardiac Function in Rheumatoid Arthritis: An Observational Study","volume":"9","author":"M Baniaamam","year":"2020","journal-title":"J. Clin. Med"},{"key":"pone.0253793.ref025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14740338.2016.1218469","article-title":"Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis","volume":"15","author":"G Tocci","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0253793.ref026","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial","volume":"107","author":"ES Chung","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"pone.0253793.ref027","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","article-title":"Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"AP Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"pone.0253793.ref028","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"S van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"1","key":"pone.0253793.ref029","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3899\/jrheum.110845","article-title":"The ClASsification for Psoriatic ARthritis (CASPAR) criteria\u2014a retrospective feasibility, sensitivity, and specificity study","volume":"39","author":"W Tillett","year":"2012","journal-title":"J Rheumatol"},{"issue":"3","key":"pone.0253793.ref030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"6","key":"pone.0253793.ref031","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"JS Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0253793.ref032","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"D van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0253793.ref033","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"L Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"pone.0253793.ref034","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0735-1097(03)00329-2","article-title":"Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease","volume":"41","author":"PO Bonetti","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0253793.ref035","doi-asserted-by":"crossref","first-page":"e0169830","DOI":"10.1371\/journal.pone.0169830","article-title":"Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"12","author":"G Deyab","year":"2017","journal-title":"PLoS ONE"},{"key":"pone.0253793.ref036","doi-asserted-by":"crossref","first-page":"H12","DOI":"10.1152\/ajpheart.00226.2011","article-title":"Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones","volume":"301","author":"A Clerico","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"pone.0253793.ref037","doi-asserted-by":"crossref","first-page":"e006570","DOI":"10.1161\/CIRCHEARTFAILURE.119.006570","article-title":"Inflammation and circulating natriuretic peptide levels","volume":"13","author":"H Fish-Trotter","year":"2020","journal-title":"Circ Heart Fail"},{"key":"pone.0253793.ref038","doi-asserted-by":"crossref","first-page":"e007208","DOI":"10.1161\/CIRCHEARTFAILURE.120.007208","article-title":"Natriuretic Peptides, Inflammation, and Sounding the Alarm","volume":"13","author":"V Ramakrishnan","year":"2020","journal-title":"Circ Heart Fail"},{"key":"pone.0253793.ref039","article-title":"A Novel Role for Brain Natriuretic Peptide: Inhibition of IL-1\u03b2 Secretion via Downregulation of NF-kB\/Erk 1\/2 and NALP3\/ASC\/Caspase-1 Activation in Human THP-1 Monocyte","author":"L Mezzasoma","year":"2017","journal-title":"Mediators of Inflammation"},{"issue":"5","key":"pone.0253793.ref040","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s10753-014-9895-0","article-title":"Anti-inflammatory Effect of B-Type Natriuretic Peptide Postconditioning During Myocardial Ischemia\u2013Reperfusion: Involvement of PI3K\/Akt Signaling Pathway","volume":"37","author":"G Hu","year":"2014","journal-title":"Inflammation"},{"key":"pone.0253793.ref041","doi-asserted-by":"crossref","first-page":"e014661","DOI":"10.1161\/JAHA.119.014661","article-title":"Heart Failure Risk Associated With Rheumatoid Arthritis\u2013Related Chronic Inflammation","volume":"9","author":"MJ Ahlers","year":"2020","journal-title":"Am Heart J"},{"key":"pone.0253793.ref042","doi-asserted-by":"crossref","first-page":"e7308","DOI":"10.1097\/MD.0000000000007308","article-title":"Cardiovascular disease in immune-mediated inflammatory diseases: a cross-sectional analysis of 6 cohorts","volume":"96","author":"B Fernandez-Gutierrez","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"pone.0253793.ref043","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/acr.23567","article-title":"Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis","volume":"70","author":"K Lauper","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"10","key":"pone.0253793.ref044","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","article-title":"Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis","volume":"4","author":"Natriuretic Peptides Studies Collaboration","year":"2016","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T15:08:04Z","timestamp":1672585684000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253793"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"Lionetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0253793","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}